Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study

Background: The analysis of mobile health (mHealth) data has generated innovative insights into improving allergic rhinitis control, but additive information is needed. A cross-sectional real-world observational study was undertaken in 17 European countries during and outside the estimated pollen se...

Full description

Bibliographic Details
Authors: Bédard, Annabelle, 1986-, Basagaña Flores, Xavier, Antó i Boqué, Josep Maria, García Aymerich, Judith, MASK study group
Format: article
Status:Published version
Publication Date:2020
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/46150
Online Access:http://hdl.handle.net/10230/46150
http://dx.doi.org/10.1186/s13601-020-00342-x
Access Level:Open access
Keyword:Allergic rhinitis
Anti-histamines
Corticosteroids
ICT
MASK
Mobile health
Treatment
id ES_109646bda91c843f431865faa3abfe07
oai_identifier_str oai:recercat.cat:10230/46150
network_acronym_str ES
network_name_str España
repository_id_str
spelling Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK studyBédard, Annabelle, 1986-Basagaña Flores, XavierAntó i Boqué, Josep MariaGarcía Aymerich, JudithMASK study groupAllergic rhinitisAnti-histaminesCorticosteroidsICTMASKMobile healthTreatmentBackground: The analysis of mobile health (mHealth) data has generated innovative insights into improving allergic rhinitis control, but additive information is needed. A cross-sectional real-world observational study was undertaken in 17 European countries during and outside the estimated pollen season. The aim was to collect novel information including the phenotypic characteristics of the users. Methods: The Allergy Diary-MASK-air-mobile phone app, freely available via Google Play and App, was used to collect the data of daily visual analogue scales (VASs) for overall allergic symptoms and medication use. Fluticasone Furoate (FF), Mometasone Furoate (MF), Azelastine Fluticasone Proprionate combination (MPAzeFlu) and eight oral H1-antihistamines were studied. Phenotypic characteristics were recorded at entry. The ARIA severity score was derived from entry data. This was an a priori planned analysis. Results: 9037 users filled in 70,286 days of VAS in 2016, 2017 and 2018. The ARIA severity score was lower outside than during the pollen season. Severity was similar for all treatment groups during the pollen season, and lower in the MPAzeFlu group outside the pollen season. Days with MPAzeFlu had lower VAS levels and a higher frequency of monotherapy than the other treatments during the season. Outside the season, days with MPAzeFlu also had a higher frequency of monotherapy. The number of reported days was significantly higher with MPAzeFlu during and outside the season than with MF, FF or oral H1-antihistamines. Conclusions: This study shows that the overall efficacy of treatments is similar during and outside the pollen season and indicates that medications are similarly effective during the year.BioMed Central202120212020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/46150http://dx.doi.org/10.1186/s13601-020-00342-xreponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésClin Transl Allergy. 2020; 10(1):62© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data mahttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/461502026-05-29T05:05:01Z
dc.title.none.fl_str_mv Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study
title Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study
spellingShingle Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study
Bédard, Annabelle, 1986-
Allergic rhinitis
Anti-histamines
Corticosteroids
ICT
MASK
Mobile health
Treatment
title_short Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study
title_full Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study
title_fullStr Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study
title_full_unstemmed Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study
title_sort Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study
dc.creator.none.fl_str_mv Bédard, Annabelle, 1986-
Basagaña Flores, Xavier
Antó i Boqué, Josep Maria
García Aymerich, Judith
MASK study group
author Bédard, Annabelle, 1986-
author_facet Bédard, Annabelle, 1986-
Basagaña Flores, Xavier
Antó i Boqué, Josep Maria
García Aymerich, Judith
MASK study group
author_role author
author2 Basagaña Flores, Xavier
Antó i Boqué, Josep Maria
García Aymerich, Judith
MASK study group
author2_role author
author
author
author
dc.subject.none.fl_str_mv Allergic rhinitis
Anti-histamines
Corticosteroids
ICT
MASK
Mobile health
Treatment
topic Allergic rhinitis
Anti-histamines
Corticosteroids
ICT
MASK
Mobile health
Treatment
description Background: The analysis of mobile health (mHealth) data has generated innovative insights into improving allergic rhinitis control, but additive information is needed. A cross-sectional real-world observational study was undertaken in 17 European countries during and outside the estimated pollen season. The aim was to collect novel information including the phenotypic characteristics of the users. Methods: The Allergy Diary-MASK-air-mobile phone app, freely available via Google Play and App, was used to collect the data of daily visual analogue scales (VASs) for overall allergic symptoms and medication use. Fluticasone Furoate (FF), Mometasone Furoate (MF), Azelastine Fluticasone Proprionate combination (MPAzeFlu) and eight oral H1-antihistamines were studied. Phenotypic characteristics were recorded at entry. The ARIA severity score was derived from entry data. This was an a priori planned analysis. Results: 9037 users filled in 70,286 days of VAS in 2016, 2017 and 2018. The ARIA severity score was lower outside than during the pollen season. Severity was similar for all treatment groups during the pollen season, and lower in the MPAzeFlu group outside the pollen season. Days with MPAzeFlu had lower VAS levels and a higher frequency of monotherapy than the other treatments during the season. Outside the season, days with MPAzeFlu also had a higher frequency of monotherapy. The number of reported days was significantly higher with MPAzeFlu during and outside the season than with MF, FF or oral H1-antihistamines. Conclusions: This study shows that the overall efficacy of treatments is similar during and outside the pollen season and indicates that medications are similarly effective during the year.
publishDate 2020
dc.date.none.fl_str_mv 2020
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/46150
http://dx.doi.org/10.1186/s13601-020-00342-x
url http://hdl.handle.net/10230/46150
http://dx.doi.org/10.1186/s13601-020-00342-x
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Clin Transl Allergy. 2020; 10(1):62
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403518413045760
score 15,812429

Similar Items